Author:
Bergman A M,Pinedo H M,Talianidis I,Veerman G,Loves W J P,van der Wilt C L,Peters G J
Publisher
Springer Science and Business Media LLC
Reference66 articles.
1. Abratt RP, Rezwoda W, Falkson G, Goedhals L, Hacking D (1994) Efficacy and safety profile of gemcitabine in non-small cell lung cancer. Phase II study. J Clin Oncol 12: 1535–1540
2. Aszalos A, Thompson K, Yin JJ, Ross DD (1999) Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (P-gP). Anticancer Res 19: 1053–1064
3. Baker CH, Banzon J, Bollinger JM, Stubbe J (1991) 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorodeoxycytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34: 1879–1884
4. Beck J, Bohnet B, Brugger D, Bader P, Dietl J, Scheper RJ, Kandolf R, Liu C, Niethammer D, Gekeler V (1998) Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with mdr1, MRP and LRP gene expression. Br J Cancer 77: 87–91
5. Bergman AM, Giaccone G, Van Moorsel CJ, Mauritz R, Noordhuis P, Pinedo HM, Peters GJ (2000) Cross-resistance in the 2′,2′-difluorodeoxycytidine (gemcitabine) resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Eur J Cancer 36: 1974–1983
Cited by
111 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献